Target Name: CDC123
NCBI ID: G8872
Other Name(s): Cell division cycle 123 | HT-1080 | Cell division cycle 123 homolog | cell division cycle 123 homolog | FLJ13863 | D123 | cell division cycle 123 | C10orf7 | OTTHUMP00000019106 | PZ32 | OTTHUMP00000019110 | OTTHUMP00000019108 | Protein D123 | CD123_HUMAN | Cell division cycle protein 123 homolog

CDC123: A Promising Drug Target and Biomarker for Cancer Treatment

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 38 million new cases and 1.8 million deaths in 2020, according to the World Health Organization (WHO). The discovery of new drug targets and biomarkers has the potential to improve cancer treatment outcomes and reduce the risk of recurrence. In this article, we will explore the details of CDC123, a protein that is involved in the cell division cycle and its potential as a drug target and biomarker for cancer treatment.

CDC123: Structure and Function

CDC123 is a protein that is expressed in a variety of tissues, including muscle, liver, and brain, among others. It is a key component of the mitotic spindle, which is a structure that pulls the chromosomes apart during cell division to ensure proper segregation during the cell cycle. In addition to its role in the cell cycle, CDC123 has also been shown to play a significant role in the regulation of cell growth, angiogenesis, and inflammation.

CDC123 has several unique features that make it an attractive drug target and biomarker for cancer treatment. One of its defining features is its ability to interact with a variety of small molecules, including drugs that have been approved for cancer treatment. This interactivity makes CDC123 a potentially promising target for cancer treatment, as it allows for the development of targeted therapies that can specifically target and inhibit the activity of CDC123.

Another significant feature of CDC123 is its role in the regulation of cell growth and angiogenesis. Cell growth is a critical factor in cancer development, and studies have shown that CDC123 plays a role in regulating cell growth by controlling the production of microtubules, which are important for cell movement and division. In addition, CDC123 has also been shown to regulate the production of new blood vessels, which is a critical factor in cancer angiogenesis.

CDC123's role in the regulation of inflammation is another potential drug target for cancer treatment. Cancer cells often exploit the immune system to evade detection and treatment, and studies have shown that CDC123 is involved in the regulation of the immune response. This involvement makes CDC123 a potential target for cancer immunotherapy, as drugs that can specifically target and inhibit the activity of CDC123 may have a significant impact on cancer treatment outcomes.

CDC123 as a Biomarker

CDC123 is also an attractive biomarker for cancer treatment, as its expression has been shown to be significantly altered in a variety of cancer types. For example, studies have shown that CDC123 expression is often elevated in a variety of breast cancer subtypes, and that it may be a useful biomarker for the detection and prognosis of these cancers.

In addition to its potential as a drug target, CDC123 has also been shown to be a potential biomarker for other types of cancer, including lung cancer, colorectal cancer, and ovarian cancer. These studies suggest that CDC123 may be a useful biomarker for the detection and prognosis of a wide range of cancer types, and that its expression may be a valuable diagnostic tool for cancer researchers.

Conclusion

In conclusion, CDC123 is a protein that is involved in the cell division cycle and has been shown to play a significant role in the regulation of cell growth, angiogenesis, and inflammation. Its unique ability to interact with a variety of small molecules and its role in the regulation of cell growth and angiogenesis make it an attractive drug target for cancer treatment. In addition, studies have shown that CDC123 may be a useful biomarker for the detection and prognosis of a wide range of cancer types. Further research is needed to fully understand the potential of CDC123 as a drug

Protein Name: Cell Division Cycle 123

Functions: Required for S phase entry of the cell cycle

More Common Targets

CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3